Dynamic Technology Lab Private Ltd Invests $1.40 Million in Inari Medical, Inc. (NASDAQ:NARI)

Dynamic Technology Lab Private Ltd bought a new stake in Inari Medical, Inc. (NASDAQ:NARI) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 33,869 shares of the company’s stock, valued at approximately $1,397,000. Dynamic Technology Lab Private Ltd owned 0.06% of Inari Medical at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in NARI. GAMMA Investing LLC grew its stake in Inari Medical by 164.7% in the second quarter. GAMMA Investing LLC now owns 704 shares of the company’s stock valued at $34,000 after acquiring an additional 438 shares during the period. Nisa Investment Advisors LLC lifted its holdings in shares of Inari Medical by 83.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock valued at $46,000 after purchasing an additional 435 shares in the last quarter. KBC Group NV grew its position in shares of Inari Medical by 39.0% in the 3rd quarter. KBC Group NV now owns 1,774 shares of the company’s stock valued at $73,000 after purchasing an additional 498 shares during the period. Benjamin F. Edwards & Company Inc. increased its stake in Inari Medical by 39.4% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock worth $89,000 after purchasing an additional 522 shares in the last quarter. Finally, Covestor Ltd raised its holdings in Inari Medical by 63.5% during the 3rd quarter. Covestor Ltd now owns 2,384 shares of the company’s stock worth $99,000 after buying an additional 926 shares during the period. Institutional investors own 90.98% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on NARI shares. Robert W. Baird upped their price target on shares of Inari Medical from $66.00 to $67.00 and gave the company an “outperform” rating in a report on Tuesday, October 29th. Truist Financial boosted their price target on Inari Medical from $46.00 to $50.00 and gave the company a “hold” rating in a report on Tuesday, October 29th. Wells Fargo & Company decreased their price objective on Inari Medical from $84.00 to $65.00 and set an “overweight” rating for the company in a report on Wednesday, July 31st. Leerink Partners started coverage on Inari Medical in a research note on Tuesday, September 3rd. They issued a “market perform” rating and a $47.00 target price on the stock. Finally, Stifel Nicolaus assumed coverage on Inari Medical in a research report on Tuesday, September 17th. They set a “hold” rating and a $50.00 price target for the company. Six equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $58.89.

Inari Medical Trading Up 2.7 %

Shares of NARI opened at $50.83 on Wednesday. The company’s fifty day simple moving average is $45.73 and its 200 day simple moving average is $47.38. The company has a market cap of $2.98 billion, a price-to-earnings ratio of -37.65 and a beta of 0.96. Inari Medical, Inc. has a 1-year low of $36.73 and a 1-year high of $67.13.

Insider Transactions at Inari Medical

In related news, CFO Mitch C. Hill sold 3,000 shares of the firm’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $45.13, for a total value of $135,390.00. Following the transaction, the chief financial officer now owns 179,600 shares in the company, valued at approximately $8,105,348. This trade represents a 1.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director William Hoffman sold 40,000 shares of the stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $45.02, for a total transaction of $1,800,800.00. Following the sale, the director now owns 601,233 shares in the company, valued at $27,067,509.66. The trade was a 6.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 186,000 shares of company stock worth $8,990,990. 10.60% of the stock is owned by company insiders.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.